Key Highlights

  • Aurora Spine Corp. (TSXV:ASG) shares advanced 11.11% to CAD 0.100 as investors weighed its resolved Royalty dispute.
  • A new non-exclusive licence covers a percutaneous sacroiliac joint implant used in the SiLO TFX system.
  • An insider Loan increase to US$2.2 million in total principal supports general corporate purposes.
  • Sales traction, financing obligations and competition in spinal devices remain important considerations.

Introduction

Aurora Spine Corp. (TSXV:ASG) is a Carlsbad, California-based developer and manufacturer of minimally invasive spinal implants and interventional pain technologies. Its portfolio includes the ZIP interspinous fusion device and the SiLO TFX Transfixing SI Joint System. A settlement of a long-running licence dispute in August 2026 remains a talking point, and shares rose 11.11% to CAD 0.100.

Why Did Aurora Spine Corp. (TSXV:ASG) Rise by 11.11% on 12 November, 2026?

Aurora Spine shares registered a 11.11% increase, reaching CAD 0.100 on 12 November 2026, a move that at this price level represents a single tick.

In August 2026 the company announced a new non-exclusive licence to a U.S. Patent covering a percutaneous sacroiliac joint implant, with a four-year term starting 11 August 2026, and the settlement of a dispute over royalty calculations.

The settlement included a cash payment of US$283,000 by Aurora, return of 2,700,000 shares and dismissal of arbitration, with a simplified royalty formula for future SiLO TFX sales.

Because the stock trades at a very low price, small orders can produce large percentage moves, so the advance should be read with that mechanics in mind.

The Business model of Aurora Spine

Aurora Spine designs, manufactures and sells spinal implants and related instruments, mainly to surgeons and hospitals in the United States.

The SiLO TFX system addresses the sacroiliac joint, a frequent source of lower back and pelvic pain, using a transfixing implant placed with a minimally invasive approach.

Its ZIP device is an interspinous fusion implant that has been evaluated in clinical work, including the REFINE study, with results published in a spine surgery journal.

Revenue arises from implant sales, with royalties payable to licensors on some products. Funding has come from share issues and loans, including support from insiders.

Growth relies on surgeon adoption, hospital approvals and reimbursement for the procedures.

Major Reasons Behind Upside

Licence Dispute Resolved

The August 2026 agreement ended arbitration and reset the royalty calculation, which reduces legal distraction.

Simplified Royalties

A simpler formula on future SiLO TFX sales may make costs easier to forecast.

Shares Returned

The return of 2,700,000 shares to Aurora and extinguishment of a related note were part of the settlement terms.

Insider Loan Support

An insider increased an existing loan by US$600,000 to US$2.2 million in total, bearing 4.5% interest and due July 2029.

Clinical Evidence

Publication of the REFINE study's 12-month results adds to the clinical record for the ZIP device.

The most recent official announcement is the August 2026 licence and financing release. Earlier in 2026 the company also reported issuance of two U.S. patents.

What Are the Major Risks Investors Should Consider?

Penny-Stock Volatility: A very low share price produces wide percentage swings.

Financing Risk: Loans must be repaid or refinanced, and new share offerings could dilute holders.

Related-Party Terms: Insider borrowing involves governance considerations.

Reimbursement: Procedure coverage can influence surgeon adoption.

Competition: Larger spine and SI-joint companies have bigger sales forces.

Regulatory Risk: Device approvals and product changes need clearance.

Execution: Sales growth may take longer than planned.

What Is the Dividend Outlook?

Aurora Spine does not pay dividends.

Capital is used for inventory, sales support, royalties and loan servicing.

Shareholder outcomes therefore depend on business growth and share-price movement.

How Does Aurora Spine Compare With Other Industry Peers?

The SI joint and spinal implant field includes SI-BONE, a U.S. specialist in sacroiliac joint fusion, and larger groups such as Globus Medical and Orthofix.

These companies have wider portfolios, greater Revenue and broader hospital relationships.

Aurora Spine is far smaller and relies on niche devices and a lean structure.

A resolved licence arrangement may help it compete for surgeon attention within its niche.

What Are the Bull and Bear Cases for TSXV:ASG?

Bull Case:

Cleaner licence terms allow management to focus on selling SiLO TFX.

Insider support shows confidence and gives working capital.

Clinical publications can help adoption.

Bear Case:

Low revenue scale and cash needs may require more funding.

Large rivals may limit growth in the SI joint segment.

Technical Levels to Watch

  • Support Zone: Past trading floors may serve as reference areas.
  • Resistance Levels: Recent highs could cap advances.
  • Volume Trends: Higher turnover would better confirm interest.
  • Momentum Indicators: Moving averages can help assess if the gain persists; Tick Size at this price distorts readings.

Outlook

Aurora Spine retains a guarded but constructive stance after clearing a licence dispute.

Selling SiLO TFX under settled terms could improve clarity.

Financial flexibility depends on sales and the insider loan.

Updates on revenue and adoption will guide expectations.